Fmr LLC Catalyst Pharmaceuticals, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 79,310 shares of CPRX stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,310

Previous 73,830 7.42%

Holding current value

$1.62 Million

Previous $1.18 Million 4.42%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$14.68 - $16.92 $80,446 - $92,721	5,480 Added 7.42%	79,310 $1.23 Million
Q1 2024 May 13, 2024	BUY	$13.18 - $17.11 $802,741 - $1.04 Million	60,906 Added 471.26%	73,830 $1.18 Million
Q4 2023 Feb 13, 2024	SELL	$11.78 - $17.29 $213,300 - $313,070	-18,107 Reduced 58.35%	12,924 $217,000
Q3 2023 Nov 13, 2023	SELL	$11.69 - $15.02 $489,027 - $628,331	-41,833 Reduced 57.41%	31,031 $362,000
Q2 2023 Aug 11, 2023	BUY	$11.5 - $18.08 $655,718 - $1.03 Million	57,019 Added 359.85%	72,864 $979,000
Q1 2023 May 11, 2023	BUY	$14.34 - $21.05 $4,316 - $6,336	301 Added 1.94%	15,845 $262,000
Q4 2022 Feb 13, 2023	SELL	$12.25 - $19.5 $329,586 - $524,647	-26,905 Reduced 63.38%	15,544 $289,000
Q3 2022 Nov 10, 2022	BUY	$7.06 - $15.52 $269,910 - $593,345	38,231 Added 906.38%	42,449 $544,000
Q2 2022 Aug 12, 2022	BUY	$6.23 - $8.57 $5,121 - $7,044	822 Added 24.2%	4,218 $30,000
Q1 2022 May 13, 2022	BUY	$5.31 - $8.31 $7,311 - $11,442	1,377 Added 68.2%	3,396 $28,000
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $2,084 - $2,980	-400 Reduced 16.54%	2,019 $14,000
Q3 2021 Nov 15, 2021	BUY	$4.85 - $6.04 $6,140 - $7,646	1,266 Added 109.8%	2,419 $12,000
Q2 2021 Aug 13, 2021	BUY	$4.29 - $6.05 $4,946 - $6,975	1,153 New	1,153 $6,000

Others Institutions Holding CPRX

# of Institutions

285

Shares Held

96.6M

Call Options Held

29.2K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.1B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account